Subscribe To
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Iovance biotherapeutics: testing shareholders' patience
Iovance Biotherapeutics is on the cusp of its first FDA approval for its TIL therapy in the treatment o...
October 22, 2023, 9:12 am
Beam: opportunity based on scd data readout in 2024
Beam Therapeutics is progressing well with its phase 1/2 BEACON study using BEAM-101 for severe sickle cell disease tre...
October 22, 2023, 6:39 am
Libtayo® (cemiplimab) neoadjuvant treatment demonstrates encouraging event-free survival in patients with resectable cutaneous squamous cell carcinoma (cscc)
89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 tr...
October 21, 2023, 12:48 pm
Trending tickers: at&t, merck-daiichi sankyo, klaviyo: trending tickers october 29, 2023
Scotiabank analysts upgrade AT&T (T) stock from "Sector Perform" to "Sector Outperform." Merck (MRK) strikes a deal worth up to $22 billion with Japan...
October 20, 2023, 5:44 pm
What's in the cards for koninklijke philips' (phg) q3 earnings?
Koninklijke Philips' (PHG) third-quarter results are likely to reflect strength in the Diagnosis & Treatm...
October 20, 2023, 3:02 pm
: lipella pharmaceuticals stock more than doubles in 3 days as fda approves ind for olp treatment
Shares of Lipella Pharmaceuticals Inc. LIPO rocketed 52.2% higher in very active tracing Friday, after the Pittsburgh-based biotechnology company’s ...
October 20, 2023, 2:47 pm
Congestive heart failure in dogs treatment plan
Congestive heart failure (CHF) occurs in dogs when their heart is no longer able to keep up with the circulatory demands of the body. CHF is character...
October 20, 2023, 2:30 pm
: merck’s keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer
Merck & Co. MRK said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-containing che...
October 20, 2023, 12:13 pm
Adial pharmaceuticals announces $4 million private placement priced at-the-market under nasdaq rules
CHARLOTTESVILLE, Va., Oct. 20, 2023 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or the “Company”), a clinical-stag...
October 20, 2023, 12:00 pm
Lipella pharmaceuticals stock more than doubles in 3 days as fda approves ind for olp treatment
Shares of Lipella Pharmaceuticals Inc. LIPO, +51.55% rocketed 52.2% higher in very active tracing Friday, after the Pittsburgh-based biotechnology com...
October 20, 2023, 10:47 am
Merck's keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer
Merck & Co. MRK, -1.53% said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-contai...
October 20, 2023, 8:13 am
Biomarin: growth drivers remain intact
During Q2 2023, BioMarin Pharmaceutical's revenues for the quarter has reached $595.3 million, a 12% YoY increase. The company's drug pipeline include...
October 19, 2023, 11:04 pm
Ipo update: chromocell therapeutics seeks $8.7 million in micro-ipo
Chromocell Therapeutics Corporation has filed for an $8.7 million IPO to develop its treatment for chro...
October 19, 2023, 5:31 pm
Pfizer sets price of covid-treatment paxlovid at $1,390
Pfizer (PFE) is pricing a five-day treatment of the COVID-19 drug Paxlovid at $1,390. Yahoo Finance Hea...
October 19, 2023, 4:50 pm
Pound sterling price news and forecast: gbp/usd break of pivotal supports risks further weakness
GBP/USD turned south in the early European session and dropped below 1.2100 after spending the Asian trading hours in a tight range near 1.2150. The r...
October 19, 2023, 12:29 pm